The Evolving Landscape of Treatment against Unresectable Malignant Pleural Mesothelioma (MPM): Novel Options and Future Outlook
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (1 June 2023) | Viewed by 2691
Special Issue Editors
Interests: cancer pharmacology; preclinical and clinical drug development
Special Issue Information
Dear Colleagues,
After a long period of nihilism and a lack of additional therapeutic options beyond pemetrexed and platinum, recent years have witnessed extraordinary progress in the research landscape of malignant pleural mesothelioma (MPM), leading to a rapidly evolving therapeutic scenario.
As in other cancers, immunotherapy with immune checkpoint inhibitors has represented a turning point in the therapeutic algorithm of unresectable MPM, with the combination of nivolumab and ipilimumab showing a significant survival benefit over standard chemotherapy in the first-line setting. However, there is increasing evidence that only a subset of patients can achieve the highest benefit, depending on specific cellular features of the tumor microenvironment. Therefore, stratified approaches to immunotherapy, including co-inhibition of checkpoint receptors and combinations with chemotherapy or other agents, are needed to improve clinical outcomes further.
Despite preclinical data supporting the role of VEGF pathway inhibition in mesothelioma, this strategy has shown conflicting results in MPM, and it is unclear where it may fit in the new treatment paradigm. Innovative approaches such as tumor treating fields have also shown preliminary promising results.
Finally, high inter-patient genetic and phenotypic heterogeneity of MPM have thus far been major hurdles for developing effective targeted treatments. Large-scale genomic profiling studies have revealed the complex genomic architecture of this disease, paving the way to a personalized therapy in molecularly selected MPM populations.
For this Special Issue, we welcome original and review papers that deal with novel therapeutic options in unresectable MPM. We are especially looking for papers that provide insights into recent developments in immunotherapy, angiogenesis inhibition, personalized (targeted) therapies, and other innovative approaches.
Dr. Maurizio D'Incalci
Dr. Giovanni Luca Ceresoli
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- malignant pleural mesothelioma
- immunotherapy
- angiogenesis inhibition
- genomic profiling
- targeted therapy
- tumor treating fields
- personalized therapy
